Related Experiment Video
Updated: Aug 17, 2025
Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
Published on: March 30, 2019
LncRNA MEG3: Potential stock for precision treatment of cardiovascular diseases
Zining Li1,2,3, Jialiang Gao1,3,4, Di Sun1,2,3
1Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Insights
Maternally expressed gene 3 (MEG3) is implicated in cardiovascular diseases by regulating cell processes like apoptosis and inflammation. This long non-coding RNA shows potential for treating conditions such as atherosclerosis and heart failure.
Area of Science:
- Molecular Biology
- Cardiovascular Research
- Genetics
Background:
- Cardiovascular diseases (CVDs) present rising prevalence and mortality, necessitating novel therapeutic strategies.
- Pathogenesis of CVDs involves inflammation, apoptosis, fibrosis, and autophagy in cardiac and endothelial cells.
- Maternally expressed gene 3 (MEG3) involvement in disease is increasingly recognized.
Purpose of the Study:
- To review the mechanistic roles of MEG3 in various diseases, particularly cardiovascular conditions.
- To highlight the therapeutic potential of MEG3 in preventing and treating CVDs.
- To explore MEG3's role in emerging fields like cardio-oncology.
Main Methods:
- Literature review of research on MEG3's mechanisms and disease associations.
- Analysis of MEG3's involvement in cell apoptosis via p53 and PI3K/Akt pathways.
- Examination of MEG3's interactions with miRNAs in cellular processes.
Main Results:
- MEG3 regulates apoptosis, inflammation, oxidative stress, and endothelial-mesenchymal transition (EMT).
- MEG3 impacts cardiomyocytes, fibroblasts, and endothelial cells, showing therapeutic potential in atherosclerosis, myocardial infarction, hypertension, and heart failure.
- MEG3 demonstrates biomarker and prognostic value in oncological diseases.
Conclusions:
- MEG3 plays diverse pathological roles in cardiovascular system cells.
- MEG3 holds significant clinical potential for cardiovascular disease prevention and treatment.
- MEG3 may be crucial in cardio-oncology, addressing tumor heart disease.
Abstract:
The prevalence and mortality rates of cardiovascular diseases are increasing, and new treatment strategies are urgently needed. From the perspective of basic pathogenesis, the occurrence and development of cardiovascular diseases are related to inflammation, apoptosis, fibrosis and autophagy of cardiomyocytes, endothelial cells and other related cells. The involvement of maternally expressed gene 3 (MEG3) in human disease processes has been increasingly reported. P53 and PI3K/Akt are important pathways by which MEG3 participates in regulating cell apoptosis. MEG3 directly or competitively binds with miRNA to participate in apoptosis, inflammation, oxidative stress, endoplasmic reticulum stress, EMT and other processes. LncRNA MEG3 is mainly involved in malignant tumors, metabolic diseases, immune system diseases, cardiovascular and cerebrovascular diseases, etc., LncRNA MEG3 has a variety of pathological effects in cardiomyocytes, fibroblasts and endothelial cells and has great clinical application potential in the prevention and treatment of AS, MIRI, hypertension and HF. This paper will review the research progress of MEG3 in the aspects of mechanism of action, other systemic diseases and cardiovascular diseases, and point out its great potential in the prevention and treatment of cardiovascular diseases. lncRNAs also play a role in endothelial cells. In addition, lncRNA MEG3 has shown biomarker value, prognostic value and therapeutic response measurement in tumor diseases. We boldly speculate that MEG3 will play a role in the emerging discipline of tumor heart disease.
Related Concept Videos
02:39lncRNA - Long Non-coding RNAs
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...